ModifieduniverahealthcarePolicy 7.01.89

Magnetic Sphincter Augmentation for the Treatment of Gastroesophageal Reflux Disease (GERD)

Customize your policy alerts

Sign up for univerahealthcare Policy 7.01.89 alerts

Get alerted when Policy 7.01.89 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines medical necessity criteria for magnetic sphincter augmentation (e.g., LINX) to treat GERD and states that use for other indications is investigational; applies to Univera Healthcare benefit determination and providers seeking coverage.

Policy Summary

Payeruniverahealthcare

PolicyMagnetic Sphincter Augmentation for the Treatment of GERD

Policy CodePolicy 7.01.89

Change TypeRevised coverage statementshiatal repair threshold updated

Effective DateOct 15, 2026

Last ReviewJun 18, 2026

Next Review DateJun 1, 2027

Key ActionObtain prior authorization documenting age ≥18, BMI <35, objective pH evidence, ≥6 months optimized therapy, and planned repair for hiatal hernia >2 cm.

SourceLink

POLICY UPDATE CHANGES

Policy statements for diagnosis and symptom management were revised, measurement for hiatal repair was decreased to 2 cm.

Annual review performed with policy intent unchanged.

18+minimum patient age (yrs)

<35BMI threshold

≥6 momin optimized therapy

2 cm

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifieduniverahealthcarePolicy 7.01.89

Magnetic Sphincter Augmentation for the Treatment of Gastroesophageal Reflux Disease (GERD)

Customize your policy alerts

Sign up for univerahealthcare Policy 7.01.89 alerts

Get alerted when Policy 7.01.89 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

Payeruniverahealthcare

PolicyMagnetic Sphincter Augmentation for the Treatment of GERD

Policy CodePolicy 7.01.89

Change TypeRevised coverage statementshiatal repair threshold updated

Effective DateOct 15, 2026

Last ReviewJun 18, 2026

Next Review DateJun 1, 2027

Key ActionObtain prior authorization documenting age ≥18, BMI <35, objective pH evidence, ≥6 months optimized therapy, and planned repair for hiatal hernia >2 cm.

SourceLink

POLICY UPDATE CHANGES

Policy statements for diagnosis and symptom management were revised, measurement for hiatal repair was decreased to 2 cm.

Annual review performed with policy intent unchanged.

18+minimum patient age (yrs)

<35BMI threshold

≥6 momin optimized therapy

2 cm

hiatal repair threshold

43284/43285CPT codes listed

Coverage Criteria for Magnetic Sphincter Augmentation (MSA)

Inferred coverage criteria

Covered when ALL of the following are met (inferred from policy text):

Optimized medical therapy: Documented optimized PPI therapy with confirmed adherence, correct pre-meal dosing, supportive lifestyle measures, and adequate trials of an initial once-daily course followed by a subsequent trial of twice-daily dosing for refractory symptoms unless there is documentation of a serious side effect

from policy guidelines

Pre-operative evaluation: Documented comprehensive pre-operative evaluation including upper endoscopy, high-resolution esophageal manometry, ambulatory pH testing, and an upper GI series (barium swallow) prior to MSA

from policy statement

Patient selection and device considerations: Patient selection documented via shared decision-making between surgeon and patient; consideration of device characteristics (long-term implant, MR-conditional up to 1.5T) and exclusion for metal allergy or other device-specific contraindications

device description and regulatory guidance

Initial coverage criteria

Covered when ALL of the following are met

MSA candidate criteria: Adult patient with proven GERD who has persistent symptoms despite maximal medical therapy and objective evidence of abnormal pH testing; shared decision-making with the surgeon considering BMI and esophageal motility as relative contraindications; hiatal hernia larger than 3 cm should be repaired at implantation per FDA labeling

Based on AGA/NICE guidance and FDA labeling

Use of magnetic sphincter augmentation for any other indication is considered investigational. This policy specifically limits coverage to the indications and criteria described elsewhere in the document; any use outside those indications should be treated as investigational and may be denied or designated as not eligible for coverage.

The LINX device is contraindicated in individuals with a known allergy to component metals. Specifically, the device should not be used in anyone who may be allergic or is allergic to titanium, stainless steel, nickel, or iron (ferrous) materials.

Evidence is limited for regression of Barrett's esophagus (BE) following magnetic sphincter augmentation. The policy states that available data are insufficient to determine improved net health outcome for BE regression, noting only a small retrospective series (Dunn 2021) and that Barrett's esophagus was an important consideration in trial selection and labeling.

Professional guidance and regulatory statements do not support MSA as a treatment for Barrett's esophagus. Multi-society guidance and NICE note no guideline recommendation for MSA to treat BE, and the FDA has stated that LINX has not been proven to treat Barrett's esophagus and patients with BE should continue appropriate management.

Coverage and medical policy criteria apply only when the member's product covers the service. If a product does not cover a service, the medical policy criteria described in this document do not apply to that benefit or member.

The policy excerpt does not include any explicit statements labeling particular LINX-related indications as not medically necessary. Absent that explicit language in this excerpt, determinations of ‘not medically necessary’ would rely on the policy's criteria, exclusions, and any contract-specific coverage rules.

Current evidence does not support using MSA to achieve regression of Barrett's esophagus. The policy indicates evidence is insufficient to conclude BE regression with MSA and professional guidance offers no recommendation for MSA to treat BE; the FDA explicitly notes LINX has not been proven to treat BE.

Some uses of MSA may be classified and administratively handled as Experimental/Investigational (E/I) or Not Medically Necessary (NMN), and codes associated with MSA procedures may not be covered under all circumstances. Coverage adjudication should follow the policy criteria, applicable E/I or NMN designations, and the member's contract.

Coding and Key Clinical Thresholds

CPT CodesCPTCovered

43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (e.g., magnetic band), including cruroplasty when performed.
43285	Removal of esophageal sphincter augmentation device

HCPCS CodesHCPCS

No codes listed

ICD-10 CodesICD-10

K21.0	Gastro-esophageal reflux disease with esophagitis.
K21.9	Gastro-esophageal reflux disease without esophagitis

inv-15: BMI threshold for coverage

BMI thresholdBody mass index less than 35 kg/m2

Source contextListed as an eligibility criterion in the policy statement for MSA

Use in prior authorizationPrior authorization must confirm BMI <35 kg/m2 as part of criteria verification

inv-16: Duration of optimized medical therapy required

Required durationDocumented adherence to at least 6 months of optimized medical therapy

Therapy componentsIncludes lifestyle modification and maximum or maximally tolerated PPI therapy

Prior Authorization, Documentation, and Provider Requirements

Prior Authorization

Prior authorization: confirm ALL coverage criteria

Submit a prior authorization request that documents ALL policy criteria are satisfied before MSA: age ≥18 years; BMI <35 kg/m2; objective evidence of pathologic acid exposure by esophageal pH monitoring; persistent daily GERD symptoms despite ≥6 months of documented optimized medical therapy including lifestyle modification and maximum or maximally tolerated PPI therapy; and if hiatal hernia >2 cm, plan for repair prior to or at time of MSA.

Age: individual is 18 years or older.
BMI: less than 35 kg/m2.
Objective pH monitoring confirming pathologic acid exposure.
At least 6 months of documented adherence to optimized medical therapy (lifestyle + PPI).
If hiatal hernia >2 cm, documentation that hernia will be repaired prior to or at MSA.

Prior Authorization

Prior authorization implied by required pre-op evaluation

Prior authorization is implied because providers must document a comprehensive pre-operative evaluation prior to MSA, typically including upper endoscopy, high-resolution esophageal manometry, pH testing, and an upper GI series (barium swallow).

Background and Rationale

Magnetic sphincter augmentation (e.g., the LINX Reflux Management System) is an implantable ring of interlinked titanium beads with magnetic cores placed around the gastroesophageal junction to augment the lower esophageal sphincter. It is intended to reduce pathologic reflux in patients with GERD who have abnormal pH testing and persistent symptoms despite maximal medical therapy; the device is MR-conditional up to 1.5 Tesla (1.5T) and may be explanted if higher-field MRI is required.

Definitions and Key Terms

inv-40: Objective evidence of pathologic acid exposure — confirmed by esophageal pH monitoring

DefinitionObjective evidence of pathologic acid exposure confirmed by esophageal pH monitoring

DocumentationSubmitted records must document objective evidence of pathologic acid exposure by esophageal pH monitoring

Role in eligibilityPositive pH monitoring is a required criterion for MSA coverage

inv-41: Major esophageal motility disorder — examples listed (achalasia, distal spasm, hypercontractile, absent contractility)

ExamplesMajor esophageal motility disorder examples include achalasia, distal esophageal spasm, hypercontractile esophagus, and absent contractility

Clinical implicationPresence of these disorders is listed as a contraindication/precaution that would preclude medical appropriateness

Policy Revision History

2026-06-18Revision - materialLatest

Annual review with revisions to policy statements for diagnosis and symptom management and hiatal repair measurement decreased to 2 cm.

2025-04-17Administrative review

Annual review performed; policy intent unchanged.

2025-01-01Administrative update

Policy Summary

Payeruniverahealthcare

PolicyMagnetic Sphincter Augmentation for the Treatment of GERD

Policy CodePolicy 7.01.89

Change TypeRevised coverage statementshiatal repair threshold updated

Effective DateOct 15, 2026

Last ReviewJun 18, 2026

Next Review DateJun 1, 2027

Key ActionObtain prior authorization documenting age ≥18, BMI <35, objective pH evidence, ≥6 months optimized therapy, and planned repair for hiatal hernia >2 cm.

SourceLink

On This Page

Prior authorization noteRecords must document at least 6 months of adherence before MSA consideration

inv-17: Hiatal hernia size threshold requiring repair (policy text)

Hiatal hernia threshold (original policy text)> 2 cm — if hiatal hernia greater than 2 cm, submitted records must indicate repair prior to or at time of MSA

Documentation requirementRecords must indicate hernia will be repaired prior to or at time of MSA when >2 cm

Implication for procedure planningConcurrent or prior hiatal hernia repair is expected for hernias exceeding the threshold

inv-18: Hiatal repair measurement (revised threshold)

Revised hiatal repair measurementMeasurement for hiatal repair was decreased to 2 cm (policy revision 06/18/26)

Policy history noteChange recorded in POLICY HISTORY/REVISION summary dated 06/18/26

Effect on documentationProviders should document hiatal hernia size with plan for repair when ≥2 cm per revised policy

Endoscopy (upper endoscopy) documented.
High-resolution esophageal manometry results included.
Esophageal pH testing results provided.
Upper GI series (barium swallow) included when performed.

Prior Authorization

Prior authorization: document preoperative workup and optimized therapy

Obtain and submit documentation that guideline-recommended preoperative workup was completed and that medical therapy was optimized before MSA is authorized: upper endoscopy, high-resolution manometry, and ambulatory pH monitoring per SAGES guidance and ACG/other guidelines.

Document comprehensive preoperative evaluation per SAGES: upper endoscopy, high-resolution manometry, ambulatory pH monitoring.
Document verification and optimization of PPI therapy as recommended by ACG (timing, adherence, and escalation to twice-daily when indicated).

Prior Authorization

Prior authorization for MSA CPT codes (43284/43285)

Request prior authorization for procedures billed with CPT 43284 (placement) or 43285 (removal) for members with GERD diagnoses (ICD-10 K21.0, K21.9); note that codes may be subject to coverage review and may not be covered under all circumstances.

CPT 43284 — placement of sphincter augmentation device (including cruroplasty when performed).
CPT 43285 — removal of esophageal sphincter augmentation device.
Use ICD-10 diagnosis codes K21.0 or K21.9 as applicable.

Prior Authorization

Prior authorization contingent on product coverage

Verify product benefit coverage before submitting authorization: medical policy criteria and prior authorization requirements apply only when the member's product covers the service, and requirements are product-dependent.

If the member's product does not cover the service, the policy criteria do not apply.
Prior authorization requirements vary by product (commercial, Medicaid, Medicare).

Step Therapy

Required prior medical therapy: ≥6 months documented

Document at least 6 months of prior medical therapy adherence before MSA authorization, including lifestyle modification and maximum or maximally tolerated PPI therapy.

Evidence of lifestyle modification (e.g., weight reduction when indicated).
Documentation of maximum or maximally tolerated PPI therapy for ≥6 months.

Step Therapy

Optimized PPI therapy required before MSA

Show optimized PPI therapy before considering MSA: confirmed adherence, correct pre-meal dosing, supportive lifestyle measures, and trials of once-daily followed by twice-daily dosing unless a serious side effect is documented.

Confirm PPI taken 30–60 minutes before a meal when indicated.
Document trial of once-daily then escalation to twice-daily dosing if symptoms persist, or documentation of serious side effects if escalation not possible.

Step Therapy

Medication optimization per guidelines before procedural therapy

Document that medication optimization was attempted per guidelines: an initial 8-week trial of once-daily PPI taken 30–60 minutes before meals with verification of timing and adherence and escalation to twice-daily dosing when indicated before labeling symptoms as refractory.

Initial 8-week once-daily PPI trial with correct timing (30–60 minutes before a meal).
Verification of adherence and dose timing, with consideration of twice-daily dosing prior to procedural therapy.

Note

Consideration of prior medical management vs procedural therapy

Consider prior medical management in shared decision-making: guidelines indicate MSA may be an alternative to continued PPI therapy or fundoplication for selected patients after optimization of medical therapy.

MSA may be chosen over continued PPI use in selected patients.
Choice between MSA and fundoplication should be individualized based on patient factors (e.g., BMI, motility).

Documentation Required

Required supporting documentation for prior authorization

Include objective supporting documentation with authorization: esophageal pH monitoring demonstrating pathologic acid exposure, documentation of ≥6 months adherence to optimized medical therapy (lifestyle + PPI), and, when applicable, documentation that hiatal hernia >2 cm will be repaired prior to or at MSA.

Esophageal pH monitoring report confirming pathologic acid exposure.
Clinical records showing ≥6 months of optimized medical therapy and adherence.
Surgical plan or notes indicating hiatal hernia repair if hernia >2 cm.

Documentation Required

Required pre‑operative documentation

Provide comprehensive pre‑operative documentation prior to MSA: upper endoscopy, high-resolution esophageal manometry, ambulatory pH monitoring, and upper GI series as part of the preoperative evaluation.

Upper endoscopy report.
High-resolution esophageal manometry results.
Ambulatory (or other) pH monitoring report.
Upper GI (barium) series when performed.

Documentation Required

Preoperative evaluation and medical management documentation (SAGES/ACG)

Document preoperative evaluation and medical management per society guidance: SAGES recommends upper endoscopy, high-resolution manometry, and ambulatory pH monitoring; also include documentation of PPI trial optimization (timing, adherence, dosing escalation).

Documentation that SAGES-recommended preoperative tests were completed.
Records verifying PPI optimization per ACG guidance (timing and adherence).

Documentation Required

Documentation of device labeling alignment and clinician qualifications

Ensure documentation demonstrates device use aligns with FDA labeling and that clinicians performing MSA have appropriate training and experience in foregut surgery and GERD management per NICE and SAGES recommendations.

Reference FDA PMA labeling where applicable.
Confirm surgeon has training/experience in foregut surgery and GERD management.

Documentation Required

Refer to device IFU and FDA PMA in documentation

When applicable, reference the LINX device Instructions for Use (IFU) and FDA PMA documents in the record to demonstrate device-specific indications, contraindications, and labeling considerations.

Torax Medical/LINX IFU (2023) and FDA PMA P100049 with supplements cited in records as relevant.
Use IFU/PMA information to confirm required hiatal hernia repair guidance and other labeling points.

Denial Risk

Contraindications/precautions — documentation to avoid denial

Absence of listed contraindications/precautions must be documented; presence of major esophageal motility disorders, LA Grade C/D esophagitis, esophageal stricture/significant anatomic abnormalities, varices, suspected/confirmed cancer, scleroderma, or allergy to device metals may preclude coverage and trigger denial.

Document absence of major motility disorders (e.g., achalasia, distal spasm, hypercontractile esophagus, absent contractility).
Document absence of LA Grade C or D esophagitis.
Document absence of strictures, varices, suspected/confirmed esophageal or gastric cancer, scleroderma, or metal allergies.

Denial Risk

Denial risk: incomplete pre‑operative evaluation

Failure to provide a comprehensive pre‑operative evaluation (endoscopy, high-resolution manometry, pH testing, upper GI series) before MSA may be grounds for denial; include these reports with authorization requests.

Missing endoscopy, manometry, or pH testing reports increases risk of denial.
Upper GI series should be included when part of the workup.

Documentation Required

Clinician qualification requirement — experienced foregut surgeons

MSA should be performed by surgeons experienced in foregut surgery and GERD management; absence of appropriate surgeon experience or performance by non‑specialists may lead to unfavorable outcomes and implicit risk for denial.

Confirm surgeon training and experience in foregut/antireflux procedures per SAGES guidance.
Do not offer MSA in isolation without appropriate multidisciplinary evaluation.

Denial Risk

Coverage exceptions and denial risk for codes

Be aware that codes for MSA may be designated E/I or NMN in some situations; coverage exceptions exist and codes may not be covered under all circumstances.

Check coverage determination for E/I (experimental/investigational) or NMN (not medically necessary) indicators.
Authorization decisions may vary by circumstance and documentation.

Prior Authorization

Contract coverage dependency — verify product benefits first

Confirm the member’s product coverage before pursuing authorization: services are contract dependent and the medical policy criteria apply only when the product covers the service.

Verify commercial, Medicaid, or Medicare product rules before authorization.
If product excludes the service, do not apply the medical policy criteria.

Prior authorization impactDocumentation should confirm absence of major esophageal motility disorder before approval

inv-42: Grade C or D esophagitis — LA classification referenced as contraindication

DefinitionGrade C or D esophagitis refers to Los Angeles (LA) classification grades C or D and is listed as a contraindication

Clinical implicationPresence of LA grade C/D esophagitis would preclude medical appropriateness for MSA

Documentation requirementPreoperative endoscopy should document esophagitis grade to confirm eligibility

inv-43: LINX Reflux Management System — device description

Device descriptionAn implantable ring composed of interlinked titanium beads with magnetic cores placed around the gastroesophageal junction to augment the lower esophageal sphincter

Intended effectMagnetic attraction augments the LES to prevent gastric reflux without compressing the esophageal wall

MR and allergy considerationsManufacturer notes device is MR-conditional up to 1.5T and contraindicated in patients allergic to component metals

inv-44: Clinical success defined as >=50% improvement in GERD-HRQL (FDA post-approval study)

Clinical success definitionClinical success defined as a ≥50% improvement in total GERD-HRQL score compared with baseline off PPIs (FDA post-approval study)

Reported resultLouie et al: clinical success achieved in 81.6% in long-term post-approval study (median follow-up ~12 months)

Use in evaluationClinical success measure used in FDA post-approval study to assess long-term outcomes

inv-45: Device explantation rate — proportion requiring removal, reported in long-term follow-up

Explantation rate (long-term)Device explantation reported up to 13% in long-term follow-up; 7-year cumulative risk of removal 4.81% (DeMarch analysis of MAUDE/manufacturer data)

Primary reasons for removalDysphagia/odynophagia (47.9%), persistent GERD (20.5%), unknown/other (11.2%)

Size associationDevice size was significantly related to explant likelihood, with smallest size having highest explant rate

inv-46: LINX device regulatory identifier referenced (FDA PMA P100049)

Regulatory identifierFDA premarket approval P100049

PMA historyP100049 received in 2012 with supplements (e.g., S021 in 2018; S037 in 2024) referenced in policy

Indication noted by FDAApproved for GERD in patients with abnormal pH testing and persistent symptoms despite maximal therapy

inv-47: LINX Reflux Management System — additional IFU/PMA identification

Additional IFU/PMA IDsDevice IFU available from manufacturer (Torax/Johnson & Johnson MedTech) and PMA supplements P100049/S001, P100049/S021, P100049/S037 referenced

Provider resourcesRefer to LINX Instructions for Use (2023) and FDA PMA documents for device-specific usage and labeling information

Policy linkagePolicy directs providers to device IFU and FDA PMA for device-specific guidance and restrictions

Summary-of-changes tracking implemented in the policy document.

2014-02-20Initial effective date

Policy originally became effective.